ESTRO 2024 - Abstract Book

S5808

RTT - Education, training, advanced practice and role developments

ESTRO 2024

HDR-brachytherapy follow-up may aid clinicians informing future patients on long-term toxicities from a patient’s perspective. Future collaboration with other HDR-brachytherapy centres will increase the sample size, facilitating statistical/correlation analyses. Increasing numbers of patients remain on long-term follow-up after radical/salvage prostate cancer treatment. PSA monitoring has a well-established role, however it is pertinent to identify late effects that may not be captured in busy clinical settings. Our findings suggest RTTs can play an important role in this.

Keywords: Radiation Therapist (RTT), PROMs, Toxicities

References:

1. Corkum M, Loblaw A, Hasan Y, Chung HT, Tseng C-L, McGuffin M, et al. Prostate high dose-rate brachytherapy as monotherapy for prosate cancer: Late toxicity and patient reported outcomes from a randomised phase II clinical trial. Radiother Oncol. 2021 Jan;156:160-165. doi: 10.1016/j.radonc.2020.12.021 2. Parzen JS, Ye H, Gustafson G, Yan D, Martinez A, Chen PY, et al. Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localised prostate cancer. Radiother Oncol. 2020 Jun;147:123-129. doi: 10.1016/j.radonc.2020.03.033 3. Hoskin PJ, Rojas AM, Ostler PJ, Bryant L, Lowe GJ. Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results. Radiother Oncol. 2021 Jan;154:214-219. doi: 10.1016/j.radonc.2020.09.047 4. Oliver LA, Hutton DP, Hall T, Cain M, Bates M, Cree A, et al. Amplifying the Patient Voice: A Survey of Practitioners’ Use of Patient-reported Outcome Measures Across Radiotherapy Providers in England. Clin. Oncol. 2022 Nov;35(3):199-208. doi: 10.1016/j.clon.2022.11.004 5. Petersen SE, Thorsen LB, Hansen S, Petersen PM, Lindberg H, Moe M, et al. A phase I/II study of acute and late physician assessed and patient-reported morbidity following whole pelvic radiation in high-risk prostate cancer patients. Acta. Oncol. 2021 Sep;61(2):179-184. doi: 10.1080/0284186X.2021.1979246 6. Rammant E, Ost P, Swimberghe M, Vanderstraeten, B, Lumen N, Decaestecker K, et al. Patient versus physician reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomised controlled trial. Strahlenther Onkol. 2019 May;195:393-401. doi: 10.1007/s00066-018-1395-y

7. Nisbet H, Caulfield L & Holloway E. An evaluation of a therapeutic radiographer led “sexual care after radiotherapy” clinic. Radiography. 2021 Aug;27(3):897-902. doi: 10.1016/j.radi.2021.02.009

8. Verma R, Treasure P & Hughes R. Development and evaluation of radiographer led telephone follow up following radical radiotherapy to the prostate. A report of a Macmillan Cancer Support Sponsored Pilot project at Mount Vernon Hospital. Radiography. 2015 Feb;21(1):16-24. doi: 10.1016/j.radi.2014.05.003 9. Hetherington SM, Gilleece T, Shepherd P, Crowther K, O’Sullivan J, Jain S, et al. TRUFU: Therapeutic radiographer undertaking follow up for prostate cancer patients. Radiography. 2018 Nov;24(4):298-303. doi: 10.1016/j.radi.2018.06.001